COMPARISON OF DIFFERENT COMBINATION CHEMOTHERAPY REGIMENS IN CHILDREN WITH ALL

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。（来自国家癌症研究所PDQ数据库的临床试验总结）化疗中使用的药物使用不同的方式来阻止癌细胞分裂，使它们停止生长或死亡。给予一种以上的药物可能会杀死更多的癌细胞。目前尚不清楚哪种联合化疗方案治疗儿童急性淋巴细胞白血病更有效。 这项随机的III期临床试验比较了不同的联合化疗方案，看看它们在治疗急性淋巴细胞白血病儿童中的效果如何。 患者将接受标准联合化疗8周。然后，患者将被随机分配到四个方案之一，进行额外的化疗。治疗可持续长达3年。有些患者也可能接受放射治疗。患者将每4-8周一次接受随访评估，持续1年，每3个月一次，持续1年，每6个月一次，持续1年，此后每年一次。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. This randomized Phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia. Patients will receive standard combination chemotherapy for 8 weeks. Patients will then be randomly assigned to one of four regimens for additional chemotherapy. Treatment may continue for up to 3 years. Some patients may also undergo radiation therapy. Patients will receive follow-up evaluations every 4-8 weeks for 1 year, every 3 months for 1 year, every 6 months for 1 year, and once a year thereafter.